In vivo drug-selectable genes: A new concept in gene therapy

Stem Cells

Volumn 15, Issue 2, 1997, Pages 104-111

  Licht, T ^a,b   Herrmann, F ^b   Gottesman, M M ^a   Pastan, I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Chemotherapy; Dihydrofolate reductase; Hematopoietic stem cells; Multidrug resistance; Myelosuppression; P glycoprotein; Retroviral vectors; Transgenic animal

Indexed keywords

CANCER THERAPY; DRUG SELECTIVITY; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; MARKER GENE; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW;

ANIMALIA;

EID: 0030989006     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150104     Document Type: Review

References (85)

1. Pirker R, Wallner J, Gotzl M et al. MDR1 RNA expression is an independent prognostic factor in acute myeloid leukemia. Blood 1992;80:557-559.
2. Zhou DC, Marie JP, Suberville AM et al. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992;6:879-885.
3. Salmon SE, Grogan TM, Miller T et al. Prediction of doxorubicin resistance in vitro in melanoma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989;81:696-701.
4. Musto P, Lombardi G, Matera R et al. The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma. Haematologica 1991;76:513-516.
5. Chan HSL, Thorner PS, Haddad G et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
6. Goldstein L, Fojo A, Ueda K et al. Expression of the multidrug resistance gene, MDR1, gene in neuroblastomas. J Clin Oncol 1990;8:128-136.
7. Norris MD, Bordow SB, Marshall GM et al. Expression of the gene for multidrug-resistance associated-protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-238.
8. Cheng A-L, Su I-J, Chen Y-C et al. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993;11:109-115.
9. Lum BL, Fisher GA, Brophy NA et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993;72(suppl 11):3502-3514.
10. Ford JM, Hait WN. Pharmacologic circumvention of multidrug resistance. Cytotechnology 1993;12:171-212.
11. Lehnert M. Reversal of P-glycoprotein associated multidrug resistance: from bench to bedside. Onkologie 1994;17:8-15.
12. Pearson JW, Fogler WE, Volker K et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991;83:1386-1391.
13. Tsuruo T, Hamada H, Sato S et al. Inhibition of multidrug-resistant human tumor cell growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 1989;80:627-631.
14. Mickisch GH, Pai LH, Siegsmund M et al. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal cell carcinomas and in MDR-transgenic mice. J Urol 1993;149:174-178.
15. Kiehntopf K, Brach MA, Licht T et al. Ribozyme mediated cleavage of MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 1994;13:4645-4652.
16. Scanlon KJ, Ishida H, Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci USA 1994;91:11123-11127.
17. Gottesman MM, Germann UA, Aksentijevitch I et al. Gene transfer of drug resistance genes. NY Acad Sci 1994;716:126-139.
18. Banerjee D, Zhao SC, Li MX et al. Gene therapy utilizing drug resistance genes: a review. STEM CELLS 1994;12:378-385.
19. Licht T, Pastan I. Gottesman MM et al. The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders. Ann Hematol 1996;72:184-193.
20. Haber DA, Beverly SM, Kiely ML et al. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J Biol Chem 1981;256:9501-9510.
21. Simonsen CC, Levinson AD. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA 1983;80:2495-2499.
22. RIII J Biol Chem 1990;265:8317-8321.
23. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-171.
24. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
25. Grant CE, Valdimarsson G, Hipfner DR et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-361.
26. Galski H, Sullivan M, Willingham MC et al. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin induced leukopenia. Mol Cell Biol 1989;9:4357-4363.
27. Mickisch GH, Licht T, Merlino GT et al. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency and toxicity. Cancer Res 1991;51:5417-5424.
28. Mickisch GH, Merlino GT, Galski H et al. Transgenic mice which express the human multidrug resistance gene in bone marrow enable a rapid identification of agents which reverse drug resistance. Proc Natl Acad Sci USA 1991;88:547-551.
29. Mickisch GH, Aksentijevich I, Schoenlein PV et al. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992;79:1087-1093.
30. Isola LM, Gordon JW. Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene. Proc Natl Acad Sci USA 1986;83:9621-9625.
31. May C, Gunther R, Mclvor RS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 1995;86:2439-2448.
32. Ferguson L, Baguley BC. Multidrug resistance and mutagenesis. Mutat Res 1993;285:79-90.
33. Gottesman MM. Multidrug-resistance during chemical carcinogenesis: a mechanism revealed? J Natl Cancer Inst 1988;80:1352-1353.
34. 6-methylguanine-DNA adducts protects transgenic mice from N-methyl-nitrosourea-induced thymic lymphomas. Cancer Res 1994;54:4648-4652.
35. 6-methylguanine DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc Natl Acad Sci USA 1993;90:6468-6472.
36. DelaFlor-Weiss E, Richardson C, Ward M et al. Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells. Blood 1992;80:3106-3111.
37. McLachlin JR, Eglitis MA, Ueda K et al. Expression of a human complementary DNA for the human multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 1990;82:1260-1263.
38. Pastan I, Gottesman MM, Ueda K et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988;85:4486-4490.
39. D'Hondt V, Caruso M, Ward M et al. Expression of the multidrug resistance gene using retroviral vectors. Blood 1995;86:466a.
40. Greenbaum M, Letourneau S, Assar H et al. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. Cancer Res 1994;54:4442-4447.
41. Doroshow JH, Metz MZ, Matsumoto L et al. Transduction of NIH 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase pi produces broad-range multidrug resistance. Cancer Res 1995;55:4073-4078.
42. Metz MZ, Best DM, Kane SE. Harvey murine sarcoma virus/MDR1 retroviral vectors: efficient virus production and foreign gene transduction using MDR1 as a selectable marker. Virology 1995;208:634-643.
43. Baum C, Hegewisch-Becker S, Eckert HG et al. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995;69:7541-7547.
44. Sorrentino BP, Brandt SJ, Bodine D et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992;257:99-103.
45. Podda S, Ward M, Himelstein A et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992;89:9676-9680.
46. Hanania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1994;1:21-25.
47. Miller AD, Law M-F, Verma IM. Generation of a helper free amphotropic retrovirus that transduces a dominant acting methotrexate resistant dihydrofolate reductase gene. Mol Cell Biol 1985;5:431-437.
48. Li M-X, Banarjee D, Zhao S-C et al. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 1994;83:3403-3408.
49. Zhao SC, Li M-X, Banerjee D et al. Long term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther 1994;1:27-33.
50. Williams DA, Hsieh K, DeSilva A et al. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate resistant bone marrow. J Exp Med 1987;166:210-218.
51. Cline MJ, Stang H, Mercola K et al. Gene transfer in intact animals. Nature 1980;284:422-425.
52. Corey CA, DeSilva AD, Holland CA et al. Serial transplantation of methotrexate resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 1990;76:337-343.
53. Lemischka IR. Clonal, in vivo behavior of the totipotent hematopoietic stem cell. Semin Immunol 1991;3:349-355.
54. Nolta JA, Dao MA, Wells S et al. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc Natl Acad Sci USA 1996;93:2414-2419.
55. Ogawa M. Differentiation and proliferation of stem cells. Blood 1993;81:2844-2853.
56. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1992;10:4239-4242.
57. Licht T, Aksentijevich I, Gottesman MM et al. Efficient expression of functional human MDR1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells. Blood 1995;86:111-121.
58. Bodine DM, Seidel NE, Gale MS et al. Efficient retrovirus transduction of mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor. Blood 1994;84:1482-1491.
59. Richardson C, Ward M, Podda S et al. Mouse fetal liver cells lack amphotropic retroviral receptors. Blood 1994;84:433-439.
60. Schwarzenberger P, Spence S, Lohrey N et al. Gene transfer of multidrug resistance into a factor-dependent human progenitor cell line: in vivo model for genetically transferred chemoprotection. Blood 1996;87:2723-2731.
61. + cells. Blood 1994;84:1408-1414.
62. Boesen JJ, Nooter K, Valerio D. Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene. Biotherapy 1993;6:291-302.
63. Bertolini F, de Monte L, Corsini C et al. Retrovirus-mediated transfer of the multidrug resistance gene into human haematopoietic progenitor cells. Br J Haematol 1994;88:318-324.
64. Ward M, Pioli P, Ayello J et al. Retroviral transfer and expression of the human multiple drug resistance (MDR) gene in peripheral blood progenitor cells. Clin Cancer Res 1996;2:873-876.
65. Deisseroth AB, Kavanagh J, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum Gene Ther 1994;5:1507-1522.
66. O'Shaughnessy JA, Cowan KH, Nienhuis AW et al. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 1994;5:891-911.
67. Hesdorffer C, Amman K, Bank A et al. Human MDR1 gene transfer in patients with advanced cancer. Hum Gene Ther 1994;5:1151-1160.
68. Sugimoto Y, Hrycyna CA, Aksentijevich I et al. Co-expression of a multidrug resistance gene (MDR1) and Herpes Simplex Virus thymidine kinase gene as a part of a bicistronic mRNA in a retrovirus vector allows selective killing of MDR1-transduced cells. Clin Cancer Res 1995;2:447-457.
69. Licht T, Aran JM, Goldenberg SK et al. Cytotoxic drug selection of murine bone marrow cells following transfer of the MDR1 (multidrug resistance) gene increases gene expression and chemoresistance in vivo. Blood 1995;86:243a.
70. Richardson C, Bank A. Preselection of transduced murine hematopoietic stem cell populations leads to increased long-term stability and expression of the human multiple drug resistance gene. Blood 1995;86:2579-2589.
71. Dunbar CE, Bodine DM, Sorrentino B et al. Gene transfer into hematopoietic cells: implications for cancer therapy. Ann NY Acad Sci 1994;716:216-224.
72. + bone marrow cells. Blood 1993;82:1975-1980.
73. Emerman M, Temin HH. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984;39:459-467.
74. Emerman M, Temin HH. Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol Cell Biol 1986;6:792-800.
75. Olsen JC, Johnson LG, Wong-Sun ML et al. Retrovirus-mediated gene transfer to cystic fibrosis airway epithelial cells: effect of selectable marked sequences on long-term expression. Nucleic Acids Res 1993;21:663-669.
76. Germann UA, Gottesman MM, Pastan I. Expression of a multidrug resistance-adenosine deaminase fusion gene. J Biol Chem 1989;264:7418-7424.
77. Germann UA, Chin K-V, Pastan I et al. Retroviral transfer of a chimeric multidrug resistance-adenosine deaminase gene. FASEB J 1990;4:1501-1507.
78. Aran JM, Germann UA, Gottesman MM et al. Construction and characterization of a selectable multidrug resistance-gluco-cerebrosidase fusion gene. Cytokines Mol Ther 1996;2:47-57.
79. Sugimoto Y, Aksentijevich I, Gottesman MM et al. Efficient expression of drug-selectable genes under control of an internal ribosome entry site. Biotechnology 1994;12:694-698.
80. Metz MZ, Matsumoto L, Winters KA et al. Bicistronic and two-gene retroviral vectors for using MDR1 as a selectable marker and a therapeutic gene. Virology 1996;217:230-241.
81. Aran JM, Gottesman MM, Pastan I. Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci USA 1994;91:3176-3180.
82. Aran JM, Licht T, Gottesman MM et al. Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy. Hum Gene Ther 1996;7:2165-2175.
83. Sugimoto Y, Aksentijevich I, Murray G et al. Retroviral Co-expression of a multidrug-resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Hum Gene Ther 1995;6:905-915.
84. Sokolic RA, Sekhsaria S, Sugimoto Y et al. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Blood 1996;87:42-50.
85. Aran JM, Licht T, Gottesman MM et al. Design of a multidrug-resistance-marking vector. Proc Am Assoc Cancer Res 1995;36:336.